Navigation Links
Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Date:11/19/2008

MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX: SYI) today announced that it has submitted, and that the FDA has received its application for 510(k) clearance for its HAPTOCHEK(TM) diagnostic test kit. The 510(k) submission begins a 90-day review process, during which the FDA will determine whether the kit can be distributed to labs throughout the country as an in vitro diagnostic.

"We are very pleased to announce the submission of a 510(k) application for our test kit to the FDA, as it demonstrates that we are continuing to execute on our business plan," said Noah Berkowitz, M.D., President and CEO of Synvista Therapeutics. "We believe that, once cleared by the FDA, our test will become an important facilitator of personalized medicine and may provide a standard by which physicians can influence clinical outcome."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing clinical diagnostic laboratory tests and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a protein-based clinical laboratory test to identify patients with Hp2-2 diabetes. Tests which identify patients with Hp2-2 diabetes may be useful in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral antioxidant drugs to treat the HDL dysfunction seen in Hp2-2 diabetes, a disease affecting almost 7 million patients in the United States. The Company is also developing alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for the treatment of systolic and diastolic heart failure.

For more information, please visit the Company's Web site at www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' diagnostic tests and product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Synvista Therapeutics Posts Letter to Stockholders on Web Site
11. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 ... ... a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved ... interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... today announced the appointment of Joshua F. Coleman , ... Dr. Coleman will oversee clinical content development and curation of ... software suite empowers molecular pathologists with a seamless workflow for ... from quality control through reporting. ... , , ...
(Date:11/30/2016)... RATON, Fla. , Nov. 30, 2016 ... biotherapeutic products, is pleased to announce the addition of ... Avenue Kearney, Nebraska . The 15,200 ... business on November 29th, 2016 and brings the total ... Ileana Carlisle , BPC,s Chief Executive ...
Breaking Biology Technology:
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
Breaking Biology News(10 mins):